Abstract
Objective: Since 1999, the lithotriptor LDM<sup>®</sup> (Philips, Germany) is used routinely for treatment of urinary stones in our department. We evaluated the complication rate and treatment success of extracorporeal stone treatment with the new lithotriptor. Material and Methods: We performed a prospective, two-step clinical study: (1) Complication rate: From January to May 1999, 312 consecutive treatments in 225 patients (136 male, 89 female) were evaluated. (2) Success rate: From February to April 2000, 88 consecutive patients (61 male, 27 female) with 113 concrements were evaluated. Results: (1) Complication rate: Overall complication rate was 10%. Most of them were minor complications. Most significant complications were subcapsular renal hematomas, which were detected by routinely performed renal ultrasound in 1%. (2) Success rate: After single treatment, overall success rate was 87%. 15 of 16 in situ treated ureteral stones (94%) were sufficiently disintegrated by a single treatment. Disintegration rates after single treatment were 93.6% for renal stones smaller than 1 cm and 86% for renal stones 1–2 cm, respectively. Conclusions: Stone therapy by SWL with the new lithotriptor LDM is a highly effective therapy of renal and ureteral stones and has a low complication rate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
